Ahead of its annual general meeting, footwear retailer Dr Martens said it is trading “in line with expectations” so far during this financial year and confirmed that all guidance for the 2026 financial year remains unchanged.
The footwear specialist said its autumn/winter order books globally are “healthy” and its performance is anticipated to be weighted to the second half, “particularly from a profit perspective”.
With an eye to individual markets, Dr Martens hailed “positive trading” in its Americas direct-to-consumer (DTC) channel, which was particularly boosted by full-price retail sales.
Dr Martens added that its EMEA DTC business remains “more variable” as a result of an ongoing “challenging trading backdrop” in the UK.
In the Asia Pacific, Dr Martens said it is seeing “good growth” and highlighted South Korea and its “well established shoe category” as a strong performer.
Dr Martens told the City: “We are focused on embedding our new consumer-first ‘Levers for Growth’ strategy, which we outlined at our results on June 5 and which builds on the work undertaken in FY25 to stabilise the business.
“The strategy capitalises on the clear strengths of the business today and taps into the significant new markets and profit pools that are available to us. It is centred on engaging more consumers, driving more product purchase occasions, curating market-right distribution and simplifying the operating model.
“Further details on our early progress in these areas will be shared at our first half results in November.”
This comes after the retailer pledged to have “brought stability back” to the business during the 2025 financial year.
In June, Dr Martens reported a fall in profits and sales for the 52 weeks to March 30, 2025.
No comments yet